Table I.

Clinical response data and correlation with PD-1, PD-L1 and NUR77 mRNA expression at days 5–28.

Patient ID	Sex/age (years)	Diagnosis/treatment	Best response	PD-1 inductiona	PD-L1 inductiona	NUR77 inductiona
0007	M 58	AMLb	Resistant	No	Yes	No
0021	F 78	AMLb	Resistant	No	Yes	No
003	M 75	AMLc	Resistant	Yes	Yes	Yes
010	F 65	AMLc	Resistant	Yes	Yes	Yes
0013	M 79	MDSb	SD	Yes	Yes	Yes
009	F 89	MDSc	PD	No	Yes	Yes
12	F 59	MDSc	PR	No	No	Yes
002	M 60	AMLc	PR	Yes	No	Yes
001	M 45	MDSc	CR	Yes	Yes	No
005	M 78	MDSc	CR	No	No	No
006	F 90	MDSc	CR	No	Yes	Yes
007	M 64	AMLc	CR	No	No	No
15	M 77	MDSb	NE	No	No	Yes

^a>2 fold induction in gene expression following treatment commenced during cycle 1 (days 5–28). PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; NUR77, orphan nuclear receptor NUR77; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; M, male; F, female; NE, not evaluated.

^bEpigenetic treatment with azacytidine and LBH-589.

^cEpigenetic treatment with azacytidine alone.